公司资料

Jade Biosciences 股价、新闻与催化剂

股票代码:
JBIO
交易所:
NASDAQ
行业:
Biopharma
所在地:
United States

股票表现

15.06 USD (-2.78%)

收盘价

最后更新: 2026年11月19日

—

市值

股价为何变动

截至 2026年11月19日,JBIO 下跌 2.78%,收于 $15.06。当前新闻监测窗口内未发现新的同公司新闻。

公司概览

业务概览

Aerovate Therapeutics is a pulmonary-hypertension company focused on inhaled and respiratory-delivery therapies. Its business has been shaped by clinical execution in a high-catalyst disease area.

所在地与行业分类

Headquartered in the United States and listed on NASDAQ, Aerovate sits in specialty biopharma.

商业模式特征

The model depends on clinical data, delivery strategy, and the ability to create value in pulmonary vascular disease.

生物医药行业定位

Aerovate is a high-beta pulmonary name whose stock is highly sensitive to trial and strategy updates.

未来催化剂

  • Aerovate Therapeutics's catalysts are strategic repositioning and any new development path after the pulmonary-hypertension reset. The company is more of a corporate-reset story now.

近期新闻

新闻标题由机器翻译,详情为英文原文。

    相似股票

    商业成熟度、治疗领域或催化剂模式相近的同行公司。